Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/30/2890702/0/en/Prime-Medicine-to-Present-at-Upcoming-Investor-Conferences.html
https://www.globenewswire.com/news-release/2024/05/13/2880364/0/en/Prime-Medicine-to-Present-at-H-C-Wainwright-2nd-Annual-BioConnect-Investor-Conference-at-NASDAQ.html
https://www.globenewswire.com/news-release/2024/05/10/2879586/0/en/Prime-Medicine-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Updates.html
https://www.globenewswire.com/news-release/2024/05/08/2877744/0/en/Prime-Medicine-Presents-Preclinical-Data-Demonstrating-Ability-of-PM359-to-Efficiently-Reproducibly-and-Durably-Correct-Causative-Mutation-of-Chronic-Granulomatous-Disease-CGD.html
https://www.globenewswire.com/news-release/2024/05/01/2873211/0/en/Prime-Medicine-to-Participate-in-the-27th-Annual-Milken-Institute-Global-Conference.html
https://pharmaphorum.com/news/prime-editing-comes-age-fda-clears-human-trials
https://www.globenewswire.com/news-release/2024/04/29/2871079/0/en/Prime-Medicine-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-Application-for-PM359-for-the-Treatment-of-Chronic-Granulomatous-Disease-CGD.html
https://www.globenewswire.com/news-release/2024/04/23/2867595/0/en/Prime-Medicine-to-Present-Preclinical-Data-Demonstrating-Broad-Potential-of-Prime-Editing-Technology-at-Upcoming-Scientific-Meetings.html
https://www.globenewswire.com//news-release/2024/03/01/2838780/0/en/Prime-Medicine-Reports-Full-Year-2023-Financial-Results-and-Provides-Business-Updates.html
https://www.globenewswire.com//news-release/2024/02/28/2836896/0/en/Prime-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html